Summary
Binding and growth promoting effects of insulin, insulin analogues modified in the B chain, proinsulin, insulin-like growth factor-I and -II were studied in cultured rat aortic smooth muscle cells. Specific binding of125I-insulin was 0.9±0.2% of total 125I-insulin added, and the IC50-value was estimated to 8.9 pmol/1. The insulin analogue B10 Asp tended to be more potent than insulin in displacing 125I-insulin, B28 Asp was equipotent, B9 Asp/B27 Glu was approximately 100 times less potent and insulin-like growth factor-I more than 1000 times less potent than insulin. Specific binding of 125I-insulin-like growth factor-I after 4 h incubation at 10 °C was five times higher than the specific binding of insulin (4.4±0.4% of total 125I-insulin-like growth factor-I added), and the IC50-value was 0.3 nmol/l. Insulin was approximately 500 times less potent than insulin-like growth factor-I in displacing 125I-insulin-like growth factor-I. The insulin analogue B10 Asp was slightly more potent and analogue B28 Asp was equipotent with insulin. Analogue B9 Asp/B27 Glu was ten times less potent and proinsulin was more than ten times less potent than insulin. The order of potency was similar for 3H-thymidine incorporation into DNA: insulin-like growth factor-I > B10 Asp > insulin-like growth factor-II > insulin > B28 Asp > B9 Asp/B27 Glu > proinsulin. The maximal effect of insulin-like growth factor-I on 3H-thymidine incorporation was 71±16% higher than the maximal effect of insulin. The maximal effect of insulin-like growth factor-II was at least as high as the effect of insulin-like growth factor-I. Furthermore, the maximal effect of B10 Asp was 62±10% higher than the maximal effect of insulin. Insulin-like growth factor-I and B10 Asp tended to increase cell number more than insulin. In conclusion, this study shows that insulin analogues interact with different potencies with receptors for insulin and insulin-like growth factor-I in vascular smooth muscle cells and that insulin-like growth factors and the insulin analogue B10 Asp have more pronounced growth effects than insulin. Substitution of the amino acid Asp for His at position B10 in insulin makes the molecule more similar to insulin-like growth factor-I, chemically and probably also biologically.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, Melberg SG, Norris F, Norris K, Snel L, Sørensen AR, Voigt HO (1988) Monomeric insulins obtained by protein engineering and their medical implications. Nature 333: 679–682
Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, Coussens L, Liao Y-C, Tsubokawa M, Mason A, Seeburg PH, Grundfeld C, Rosen OM, Ramachandran J (1985) Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313: 756–761
Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E, Jacobs S, Francke U, Ramachandran J, Fujita-Yamaguchi Y (1986) Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5: 2503–2512
King GL, Goodman AD, Buzney S, Moses A, Kahn CR (1985) Receptors and growth-promoting effects of insulin and insulin- like growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest 75: 1028–1036
Bornfeldt KE, Arnqvist HJ, Dahlkvist HH, Skottner A, Wikberg JES (1988) Receptors for insulin-like growth factor-I in plasma membranes isolated from bovine mesenteric arteries. Acta Endocrinol 117: 428–434
Pfeifle B, Ditschuneit HH, Ditschuneit H (1982) Binding and biological actions of insulin-like growth factors on human arterial smooth muscle cells. Horm Metab Res 14: 409–414
Kaiser N, Tur-Sinai A, Hasin M, Cerasi E (1985) Binding, degradation, and biological activity of insulin in vascular smooth muscle cells. Am J Physiol 249: E292-E298
Cascieri MA, Chicchi GG, Hayes NS, Slater EE (1986) Stimulation of DNA synthesis in rat A10 vascular smooth muscle cells by threonine-59 insulin-like growth factor-I. Circ Res 59: 171–177
Lee PDK, Hintz RL, Rosenfeld RG, Benitz WE (1988) Presence of insulin-like growth factor receptors and lack of insulin receptors on fetal bovine smooth muscle cells. In Vitro Cell Devel Biol 24: 921–926
Stout RW (1987) Insulin and atheroma — an update. Lancet I: 1077–1079
King GL (1985) Cell biology as an approach to the study of the vascular complications of diabetes. Metabolism 34 [Suppl. 1]: 17–24
Nilsson J, Ksiazek T, Heldin C-H, Thyberg J (1983) Demonstration of stimulatory effects of platelet-derived growth factor on cultivated rat arterial smooth muscle cells. Exp Cell Res 145: 231–237
Ham RG (1965) Clonal growth of mammalian cells in a chemically defined, synthetic medium. Proc Natl Acad Sci USA 53: 288–293
Ross R (1971) The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol 50: 172–186
Skalli O, Ropraz P, Trzeciak A, Benzonana G, Gillssen D, Gabbiani G (1986) A monoclonal antibody against α-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol 103: 2787–2796
Nilsson J, Thyberg J (1982) Fine structure of arterial smooth muscle cells cultured in the presence of whole blood serum or plasma-derived serum. Cell Tissue Res 223: 87–99
Nilsson J, Ksiazek T, Thyberg J (1983) Effects of colchicine on DNA synthesis, endocytosis and fine structure of cultivated arterial smooth muscle cells. Exp Cell Res 143: 367–375
Goldstein JL, Brown MS (1974) Binding and degradation of lowdensity lipoproteins by cultured human fibroblasts. J Biol Chem 249: 5153–5162
Skottner A, Fryklund L, Hansson HA (1986) Experimental research on IGF-I. Acta Paediatr Scand 325: 107–111
Waud DR (1975) Analysis of dose-response curves. In: Daniel EE, Paton DM (eds) Methods in pharmacology, Vol 3. Plenum Press, New York, pp 471–506
Marquardt DW (1963) An algorithm for least-squares estimation of non-linear parameters. J Soc Indust Appl Math 11: 431–441
Drejer K, Kruse V, Larsen UD (1988) Insulin analogs: binding to the human liver cell line, HEP G2. Diabetes Res Clin Pract 5 [Suppl 1]: 231
Limbird E (1986) tCell surface receptors: a short course on theory and methods, 3rd edn. Martinus Nijhoff, Boston
Elgin RG, Busby WH Jr, Clemmons DR (1987) An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I. Proc Natl Acad Sci USA 84: 3254–3258
Ross M, Francis GL, Szabo L, Wallace JC, Ballard FJ (1989) Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1–3)-IGF-1. Biochem J 258: 267–272
Ritvos O, Ranta T, Jalkanen J, Suikkari A-M, Voutilainen R, Bohn H, Rutanen E-M (1988) Insulin-like growth factor (IGF) binding protein from human decidua inhibits the binding and biological action of IGF-I in cultured choriocarcinoma cells. Endocrinology 122: 2150–2157
McCusker RH, Clemmons DR (1988) Insulin-like growth factor binding protein secretion by muscle cells: effect of cellular differentiation and proliferation. J Cell Physiol 137: 505–512
Clemmons DR, Elgin RG, Han VKM, Casella SJ, D'Ercole AJ, Van Wyk JJ (1986) Cultured fibroblast monolayers secrete aprotein that alters the cellular binding of somatomedin-C/insulinlike growth factor I. J Clin Invest 77: 1548–1556
Bowman WC, Rand MJ (1980) Principles of drug action. In: Textbook of pharmacology, 2nd English edn. Blackwell Scientific Publications, Oxford, pp 1.39–69
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bornfeldt, K.E., Gidlöf, R.A., Wasteson, A. et al. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 34, 307–313 (1991). https://doi.org/10.1007/BF00405001
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00405001